KA: AI 评分 45/100 — AI 分析 (4月 2026)

Kineta, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for oncology, neuroscience, and biodefense. The company collaborates with industry and government partners to advance its pipeline.

Key Facts: Price: $0.57 AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Kineta, Inc. pioneers innovative immunotherapies for oncology, neuroscience, and biodefense, leveraging strategic partnerships with industry giants like Pfizer and Genentech to drive clinical development and address unmet medical needs in high-growth markets, offering significant potential for long-term value creation.

KA是做什么的？

Kineta, Inc., founded in 2007 and based in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies. Originally named Lecura, Inc., the company rebranded to Kineta to reflect its broader focus on harnessing the power of the immune system to treat a range of diseases. Kineta's core focus lies in oncology, neuroscience, and biodefense, where it aims to address significant unmet medical needs through novel therapeutic approaches. The company's pipeline includes programs targeting cancer, neurological disorders, and threats to national security. Kineta operates through strategic partnerships with private, government, and industry organizations, including collaborations with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. These partnerships provide Kineta with access to resources, expertise, and funding to accelerate the development and commercialization of its immunotherapies. Kineta's approach involves identifying and developing novel drug candidates that modulate the immune system to fight disease. The company's research and development efforts are focused on advancing its pipeline of preclinical and clinical-stage programs, with the goal of bringing innovative therapies to patients in need. With a small team of 11 employees, Kineta relies heavily on its partnerships and external collaborations to drive its research and development efforts.

KA的投资论点是什么？

Investing in Kineta, Inc. (KA) presents a compelling opportunity due to its focus on high-growth immunotherapy markets within oncology, neuroscience, and biodefense. The company's strategic partnerships with industry leaders like Pfizer and Genentech validate its technology and provide access to significant resources. With a market capitalization of $0.01 billion, KA offers substantial upside potential if its clinical programs succeed. Key value drivers include advancing its pipeline of immunotherapies through clinical trials, securing additional partnerships, and achieving regulatory milestones. The company's negative P/E ratio of -1.46 reflects its current investment in research and development, but successful clinical outcomes could drive significant revenue growth and shareholder value. The high gross margin of 162.9% suggests strong potential profitability upon commercialization of its products.

KA在哪个行业运营？

Kineta operates in the rapidly evolving biotechnology industry, specifically within the immunotherapy sector. The global immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system and its role in fighting diseases like cancer. The competitive landscape includes established pharmaceutical companies and smaller biotech firms, such as BIOR, CSCI, ENTO, EPIX and FRTX, all vying for market share. Kineta differentiates itself through its focus on oncology, neuroscience, and biodefense, as well as its strategic partnerships with industry leaders. The company's success depends on its ability to develop and commercialize innovative immunotherapies that address unmet medical needs.

Biotechnology

Healthcare

KA有哪些增长机遇？

Advancing Oncology Immunotherapy Programs: Kineta has the opportunity to develop novel cancer immunotherapies. The global oncology market is projected to reach $350 billion by 2030. Successfully developing and commercializing a new cancer therapy could generate significant revenue for Kineta, with potential FDA approval within the next 3-5 years.
Expanding Neuroscience Pipeline: Kineta can expand its focus on neurological disorders. The market for neuroscience therapeutics is growing, driven by an aging population and increasing prevalence of neurological diseases. Kineta's expertise in immunology could lead to the development of new therapies for conditions like Alzheimer's disease and multiple sclerosis, with potential clinical trials starting in the next 2-3 years.
Developing Biodefense Solutions: Kineta can capitalize on the growing need for biodefense solutions. Governments worldwide are investing in research and development to protect against biological threats. Kineta's expertise in immunology could be leveraged to develop vaccines and therapies for biodefense applications, with potential government contracts within the next 1-2 years.
Leveraging Strategic Partnerships: Kineta can strengthen its relationships with existing partners like Pfizer and Genentech. These partnerships provide access to resources, expertise, and funding that can accelerate the development and commercialization of Kineta's immunotherapies. Expanding these partnerships or forming new collaborations could further enhance Kineta's growth prospects, with potential new partnership agreements in the next year.
Securing Government Funding and Grants: Kineta can pursue government funding and grants to support its research and development efforts. Government agencies like the National Institutes of Health (NIH) and the Department of Defense (DOD) offer grants for innovative research in areas like oncology, neuroscience, and biodefense. Securing these grants could provide Kineta with non-dilutive funding to advance its pipeline, with potential grant awards within the next 6-12 months.

Market Cap of $0.01 billion indicates micro-cap status with potential for high growth.
Negative P/E ratio of -1.46 reflects ongoing investment in research and development.
Gross Margin of 162.9% suggests strong potential profitability upon commercialization.
Beta of 0.57 indicates lower volatility compared to the overall market.
Strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. validate technology and provide resources.

KA提供哪些产品和服务？

Develops immunotherapies for oncology.
Develops immunotherapies for neuroscience.
Develops immunotherapies for biodefense.
Partners with private organizations for research and development.
Partners with government organizations for research and development.
Partners with industry organizations for research and development.

KA如何赚钱？

Develops and patents novel immunotherapies.
Out-licenses or co-develops therapies with partners.
Receives upfront payments, milestone payments, and royalties from partners.
Pursues government grants and contracts for research funding.

Pharmaceutical companies (e.g., Pfizer, Genentech).
Government agencies (e.g., NIH, DOD).
Patients with cancer, neurological disorders, and infectious diseases.

Proprietary immunotherapy technologies.
Strategic partnerships with leading pharmaceutical companies.
Expertise in oncology, neuroscience, and biodefense.
Intellectual property portfolio protecting its drug candidates.

什么因素可能推动KA股价上涨？

Upcoming: Clinical trial results for lead immunotherapy candidates.
Upcoming: Potential new partnerships with pharmaceutical companies.
Upcoming: Grant awards from government agencies.
Ongoing: Advancing pipeline through preclinical and clinical development.
Ongoing: Expansion of intellectual property portfolio.

KA的主要风险是什么？

Potential: Clinical trial failures could delay or halt development.
Potential: Regulatory hurdles could delay or prevent approval.
Ongoing: Competition from larger pharmaceutical companies with more resources.
Ongoing: Dependence on partnerships for funding and development.
Ongoing: Dilution risk from future equity offerings.

KA的核心优势是什么？

Strategic partnerships with major pharmaceutical companies.
Focus on high-growth immunotherapy markets.
Proprietary technology platform.
Experienced management team.

KA的劣势是什么？

Limited financial resources.
Small number of employees.
Dependence on partnerships for funding and development.
Early-stage clinical pipeline.

KA有哪些机遇？

Expanding pipeline through internal development and acquisitions.
Securing additional partnerships with pharmaceutical companies.
Obtaining government grants and contracts.
Commercializing its immunotherapies.

KA面临哪些威胁？

Competition from larger pharmaceutical companies.
Clinical trial failures.
Regulatory hurdles.
Intellectual property challenges.

KA的竞争对手是谁？

Bio-key International, Inc. — Focuses on identity and access management solutions. — (BIOR)
CSC Innovation Holdings Limited — Operates as an investment holding company. — (CSCI)
Ento Holdings Limited — Provides human resources and manpower solutions. — (ENTO)
ESSA Pharma Inc. — Develops small molecule drugs for prostate cancer. — (EPIX)
Frontage Holdings Corporation — Provides contract research services. — (FRTX)

Key Metrics

Price: $0.57 (-30.77%)
Market Cap: $8.0M
MoonshotScore: 45/100

常见问题

What does Kineta, Inc. (KA) do?

Kineta, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel immunotherapies. Their primary focus is on oncology, neuroscience, and biodefense, where they aim to address unmet medical needs by modulating the immune system to fight disease. Kineta partners with private, government, and industry organizations, including collaborations with Pfizer and Genentech, to advance its pipeline of preclinical and clinical-stage programs. The company's goal is to bring innovative therapies to patients in need through strategic partnerships and internal research and development efforts.

Is KA stock a good buy?

Evaluating whether KA stock is a good buy requires careful consideration of its potential and risks. Kineta's focus on high-growth immunotherapy markets and strategic partnerships with industry leaders like Pfizer and Genentech present significant upside potential. However, the company's micro-cap status, negative P/E ratio, and dependence on partnerships also pose risks. Investors should assess their risk tolerance and conduct thorough due diligence before investing in KA, considering factors such as clinical trial results, regulatory milestones, and the company's financial position. The high gross margin of 162.9% suggests strong potential profitability upon commercialization of its products.

What are the risks of investing in KA?

Investing in Kineta (KA) carries several risks inherent to the biotechnology industry and the company's specific situation. One significant risk is the potential for clinical trial failures, which could delay or halt the development of its immunotherapy candidates. Regulatory hurdles and competition from larger pharmaceutical companies also pose challenges. Furthermore, Kineta's dependence on partnerships for funding and development creates vulnerability if these relationships are disrupted. The company's small market capitalization and ongoing need for capital raise the risk of dilution for existing shareholders. Investors should carefully consider these risks before investing in KA.

What catalysts could move KA stock?

Several potential catalysts could significantly impact KA stock. Positive clinical trial results for Kineta's lead immunotherapy candidates would likely drive investor interest and increase the stock price. Securing new partnerships with pharmaceutical companies or receiving grant awards from government agencies could also serve as catalysts. Advancements in the company's pipeline through preclinical and clinical development, as well as expansion of its intellectual property portfolio, could further contribute to positive stock movement. FDA approval of any of their drugs would be a major catalyst.

What is KA stock price target?

As of March 2, 2026, there is no readily available analyst consensus price target for KA stock due to its micro-cap status and limited analyst coverage. Determining a fair value estimate would require a detailed analysis of Kineta's pipeline, partnerships, financial projections, and the overall market conditions. Investors should conduct their own due diligence and consider various valuation methods to assess the potential upside for KA stock, taking into account the inherent risks and uncertainties associated with biotechnology investments.